Seeking Alpha

AbbVie (ABBV) and Roche (RHHBY.OB) have halted five studies of their ABT-199 drug for leukemia...

AbbVie (ABBV) and Roche (RHHBY.OB) have halted five studies of their ABT-199 drug for leukemia and lymphoma after two patients died of tumor lysis syndrome, when the rapid destruction of malignant cells causes acute kidney failure. The firms are working to refine the dose to overcome the problem and hopes to start Phase III testing of ABT-199 this year, as planned.
Comments (2)
  • dsr70
    , contributor
    Comments (1415) | Send Message
     
    So the drug worked too well?
    18 Feb 2013, 04:09 AM Reply Like
  • wigit5
    , contributor
    Comments (3970) | Send Message
     
    Sad to hear people died, but I hope this brings ABBV down to a range I feel comfortable getting in at.
    18 Feb 2013, 10:38 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|